Baidu
map

Dermatol Surg:长期用氢氯噻嗪或增皮肤癌风险

2016-10-23 梅斯医学 梅斯医学

氢氯噻嗪是一种降压的老药,近期来自美国佛罗里达州州立大学Mohs显微手术中心皮肤肿瘤科几位医师的研究表明,氢氯噻嗪或会增加皮肤癌风险。研究者认为,氢氯噻嗪是一种已知的光敏剂,对于皮肤癌高发的人群,比如非西班牙裔白种人,减少应用或是一种有助于降低发病的因素。他们建议,这类患者尽可能更换降压药。在这项研究中,研究者共对其医疗中心5年收治的75例皮肤癌患者用药清单进行了分析。其中,终身鳞状细胞癌超过20

氢氯噻嗪是一种降压的老药,近期来自美国佛罗里达州州立大学Mohs显微手术中心皮肤肿瘤科几位专家的研究表明,氢氯噻嗪或会增加皮肤癌风险。氢氯噻嗪是一种利尿剂,但在高血压人群中,是一种最常用的降压药物之一,广泛进行单药应用,或复方应用。


研究者认为,氢氯噻嗪是一种已知的光敏剂,对于皮肤癌高发的人群,比如非西班牙裔白种人,减少应用或是一种有助于降低发病的因素。他们建议,这类患者尽可能更换降压药。

在这项研究中,研究者共对其医疗中心5年收治的75例皮肤癌患者用药清单进行了分析。其中,终身鳞状细胞癌超过20处的患者定义为高危患者。此外研究者还对1966-2015年发表的既往研究进行了回顾。

结果发现,75例患者中,有4例高危患者,且全部为非西班牙裔白种人,均服用氢氯噻嗪,服药时间为3~15年。

在相关文献中,研究者也有发现。其中3项大样本研究均显示,氢氯噻嗪与鳞状细胞癌或唇癌风险增加相关,用药5年以上者风险最高。

其中一项研究在2012年报道(AIM:降压药可能增加唇癌风险),其中降压药,主要包括氢氯噻嗪,23,616例非西班牙裔白人高血压患者的研究中,氢氯噻嗪利尿剂、氢氯噻嗪-氨苯蝶啶和钙通道阻滞剂硝苯地平与唇癌发病风险增加至少1倍有关,《内科学文献》副主编、洛杉矶卫生服务部主任Mitchell H. Katz博士指出,除了增加唇癌风险外,光敏性降压药还很可能增加皮肤基底细胞癌和鳞状细胞癌的风险。他建议临床医生应提醒患者采取简便易行的措施来减少阳光暴露。

另外一项研究也表明,氢氯噻嗪可能增加皮肤T细胞淋巴瘤的发生风险,文章发表于2013年的Cancer上。

不同的研究结果汇总都提示氢氯噻嗪的潜在风险,尤其是对皮肤或暴露在外的部位的肿瘤风险增加可能有关。

原始出处:

Cognetta AB Jr, Wolfe CM, Heinrichs E. Hydrochlorothiazide Use and Skin Cancer: A Mohs Surgeon's Concern. Dermatol Surg. 2016 Sep;42(9):1107-9.

Matsuo K, Gualtieri MR, Cahoon SS, Toboni MD, Machida H, Moeini A, Hasegawa K, Shoupe D, Roman LD. Contributing factors for menopausal symptoms after surgical staging for endometrial cancer. Menopause. 2016 May;23(5):535-43

Jahan-Tigh RR, Huen AO, Lee GL, Pozadzides JV, Liu P, Duvic M. Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series. Cancer. 2013 Feb 15;119(4):825-31.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643220, encodeId=1703164322069, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Sat Jan 07 11:05:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981016, encodeId=f2c6198101667, content=<a href='/topic/show?id=3e3fe2073e5' target=_blank style='color:#2F92EE;'>#皮肤癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72073, encryptionId=3e3fe2073e5, topicName=皮肤癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Sep 05 17:05:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061581, encodeId=90d62061581c1, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Apr 24 05:05:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152582, encodeId=09c31525820d, content=谢谢分享,临床参考价值较大!, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Tue Nov 01 09:38:40 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151021, encodeId=04cb15102134, content=癌症引发应该与服药后光照相关吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Tue Oct 25 08:06:20 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360541, encodeId=d03d136054144, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Oct 25 07:05:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150830, encodeId=8ee115083037, content=谢谢分享!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Oct 24 13:31:04 CST 2016, time=2016-10-24, status=1, ipAttribution=)]
    2017-01-07 fangcong
  2. [GetPortalCommentsPageByObjectIdResponse(id=1643220, encodeId=1703164322069, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Sat Jan 07 11:05:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981016, encodeId=f2c6198101667, content=<a href='/topic/show?id=3e3fe2073e5' target=_blank style='color:#2F92EE;'>#皮肤癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72073, encryptionId=3e3fe2073e5, topicName=皮肤癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Sep 05 17:05:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061581, encodeId=90d62061581c1, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Apr 24 05:05:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152582, encodeId=09c31525820d, content=谢谢分享,临床参考价值较大!, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Tue Nov 01 09:38:40 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151021, encodeId=04cb15102134, content=癌症引发应该与服药后光照相关吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Tue Oct 25 08:06:20 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360541, encodeId=d03d136054144, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Oct 25 07:05:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150830, encodeId=8ee115083037, content=谢谢分享!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Oct 24 13:31:04 CST 2016, time=2016-10-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1643220, encodeId=1703164322069, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Sat Jan 07 11:05:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981016, encodeId=f2c6198101667, content=<a href='/topic/show?id=3e3fe2073e5' target=_blank style='color:#2F92EE;'>#皮肤癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72073, encryptionId=3e3fe2073e5, topicName=皮肤癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Sep 05 17:05:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061581, encodeId=90d62061581c1, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Apr 24 05:05:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152582, encodeId=09c31525820d, content=谢谢分享,临床参考价值较大!, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Tue Nov 01 09:38:40 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151021, encodeId=04cb15102134, content=癌症引发应该与服药后光照相关吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Tue Oct 25 08:06:20 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360541, encodeId=d03d136054144, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Oct 25 07:05:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150830, encodeId=8ee115083037, content=谢谢分享!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Oct 24 13:31:04 CST 2016, time=2016-10-24, status=1, ipAttribution=)]
    2017-04-24 sjq027
  4. [GetPortalCommentsPageByObjectIdResponse(id=1643220, encodeId=1703164322069, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Sat Jan 07 11:05:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981016, encodeId=f2c6198101667, content=<a href='/topic/show?id=3e3fe2073e5' target=_blank style='color:#2F92EE;'>#皮肤癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72073, encryptionId=3e3fe2073e5, topicName=皮肤癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Sep 05 17:05:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061581, encodeId=90d62061581c1, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Apr 24 05:05:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152582, encodeId=09c31525820d, content=谢谢分享,临床参考价值较大!, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Tue Nov 01 09:38:40 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151021, encodeId=04cb15102134, content=癌症引发应该与服药后光照相关吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Tue Oct 25 08:06:20 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360541, encodeId=d03d136054144, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Oct 25 07:05:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150830, encodeId=8ee115083037, content=谢谢分享!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Oct 24 13:31:04 CST 2016, time=2016-10-24, status=1, ipAttribution=)]
    2016-11-01 laoli

    谢谢分享,临床参考价值较大!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1643220, encodeId=1703164322069, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Sat Jan 07 11:05:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981016, encodeId=f2c6198101667, content=<a href='/topic/show?id=3e3fe2073e5' target=_blank style='color:#2F92EE;'>#皮肤癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72073, encryptionId=3e3fe2073e5, topicName=皮肤癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Sep 05 17:05:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061581, encodeId=90d62061581c1, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Apr 24 05:05:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152582, encodeId=09c31525820d, content=谢谢分享,临床参考价值较大!, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Tue Nov 01 09:38:40 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151021, encodeId=04cb15102134, content=癌症引发应该与服药后光照相关吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Tue Oct 25 08:06:20 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360541, encodeId=d03d136054144, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Oct 25 07:05:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150830, encodeId=8ee115083037, content=谢谢分享!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Oct 24 13:31:04 CST 2016, time=2016-10-24, status=1, ipAttribution=)]
    2016-10-25 1df01bccm39(暂无匿称)

    癌症引发应该与服药后光照相关吧

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1643220, encodeId=1703164322069, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Sat Jan 07 11:05:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981016, encodeId=f2c6198101667, content=<a href='/topic/show?id=3e3fe2073e5' target=_blank style='color:#2F92EE;'>#皮肤癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72073, encryptionId=3e3fe2073e5, topicName=皮肤癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Sep 05 17:05:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061581, encodeId=90d62061581c1, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Apr 24 05:05:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152582, encodeId=09c31525820d, content=谢谢分享,临床参考价值较大!, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Tue Nov 01 09:38:40 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151021, encodeId=04cb15102134, content=癌症引发应该与服药后光照相关吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Tue Oct 25 08:06:20 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360541, encodeId=d03d136054144, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Oct 25 07:05:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150830, encodeId=8ee115083037, content=谢谢分享!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Oct 24 13:31:04 CST 2016, time=2016-10-24, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1643220, encodeId=1703164322069, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Sat Jan 07 11:05:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981016, encodeId=f2c6198101667, content=<a href='/topic/show?id=3e3fe2073e5' target=_blank style='color:#2F92EE;'>#皮肤癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72073, encryptionId=3e3fe2073e5, topicName=皮肤癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Sep 05 17:05:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061581, encodeId=90d62061581c1, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Apr 24 05:05:00 CST 2017, time=2017-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=152582, encodeId=09c31525820d, content=谢谢分享,临床参考价值较大!, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLC1BMzZWdMSPQWuib6BtQGicK8ygGBM6YakpfkRc67soFSuKbZr86enL1KggQZEZbgWSeicJibafmYfQ3AibicIHMwwicmDShfRFvvI38/0, createdBy=272a110164, createdName=laoli, createdTime=Tue Nov 01 09:38:40 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151021, encodeId=04cb15102134, content=癌症引发应该与服药后光照相关吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5rqTiaMSVSkFAupcTECOTdcVRmJQXbibJoicv5ibhcpa0vj5MGmac8wlPjuGnJISZGtOnC7rW0gbLuSE7iaEvAn0CC52ZhnRLdxtlQ/0, createdBy=1e291737907, createdName=1df01bccm39(暂无匿称), createdTime=Tue Oct 25 08:06:20 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360541, encodeId=d03d136054144, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Tue Oct 25 07:05:00 CST 2016, time=2016-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=150830, encodeId=8ee115083037, content=谢谢分享!学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Mon Oct 24 13:31:04 CST 2016, time=2016-10-24, status=1, ipAttribution=)]
    2016-10-24 xyfg98

    谢谢分享!学习了。

    0

相关资讯

JACC:低剂量的氯噻酮和氢氯噻嗪,谁抗高血压效果更好?

噻嗪类和噻嗪样利尿剂正在越来越多地以更低的剂量被使用。12.5毫克剂量的氢氯噻嗪(HCTZ)在美国仍然是最常用的处方抗高血压药物。该研究比较了氯噻酮,每天6.25毫克,与氢氯噻嗪,每天12.5毫克相比,24小时动态血压(ABP)监测和评价疗效。因为HCTZ已被认为是一种短效药,第三种比较是与加入缓释制剂后进行了比较(HCTZ可控缓释[CR])。该12周的比较,双盲,门诊研究随机分配54例1级高血压

AIM:降压药可能增加唇癌风险

《内科学文献》杂志8月6日在线发表的一项研究显示,常用的光敏性降压药物可使唇癌的发病风险增加1~3倍。氢氯噻嗪、氨苯蝶啶和硝苯地平均在此列,赖诺普利也有嫌疑(Arch. Intern. Med. 2012 Aug. 6 [doi:10.1001/archinternmed.2012.2754])。 在这项纳入23,616例非西班牙裔白人高血压患者的研究中,氢氯噻嗪利尿剂、氢氯噻嗪-氨苯蝶啶和钙通

Lancet:不同体重人群的利尿剂降压治疗存在差异

     美国学者的一项研究表明,体重正常和肥胖患者的高血压可能经由不同机制介导。基于噻嗪类的治疗对体重正常患者的心血管保护作用可能逊色于肥胖患者,但基于氨氯地平的治疗则可在不同体质指数(BMI)患者中发挥相同效应。论文于2012年12月5日在线发表于《柳叶刀》(Lancet)。   此项研究基于BMI将ACCOMPLISH试验受试人群分为肥胖(BMI ≥30,n=570

Baidu
map
Baidu
map
Baidu
map